{"id":6090,"date":"2025-02-26T15:04:44","date_gmt":"2025-02-26T14:04:44","guid":{"rendered":"https:\/\/www.ehc.eu\/uncategorized-hr\/ehc-izdaje-izjavu-o-prekidu-ili-preusmjeravanju-visestrukih-programa-lijecenja-hemofilije\/"},"modified":"2026-04-02T16:31:26","modified_gmt":"2026-04-02T14:31:26","slug":"ehc-izdaje-izjavu-o-prekidu-ili-preusmjeravanju-visestrukih-programa-lijecenja-hemofilije","status":"publish","type":"post","link":"https:\/\/www.ehc.eu\/hr\/uncategorized-hr\/ehc-izdaje-izjavu-o-prekidu-ili-preusmjeravanju-visestrukih-programa-lijecenja-hemofilije\/","title":{"rendered":"EHC izdaje izjavu o prekidu ili preusmjeravanju vi\u0161estrukih programa lije\u010denja hemofilije"},"content":{"rendered":"<!-- hero -->\t<section   class=\"subpage-hero bg-white\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"relative z-10\">\n\t\t\t\t<div class=\"pt-16 lg:pt-24 pb-24 lg:pb-32\">\n\t\t\t\t\t<div class=\"row justify-between gap-10 lg:gap-0 mt-10 text-center lg:text-left\">\n\t\t\t\t\t\t<div class=\"w-full lg:w-6\/12 lg:self-center\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"title h2\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t\t<p class=\"text-[115%]\">EHC izdaje izjavu o prekidu ili preusmjeravanju vi\u0161estrukih programa lije\u010denja hemofilije<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<figure class=\"absolute size-[41.8rem] lg:size-[82.8rem] bottom-[-10%] right-[-10rem] lg:right-[-5%] image-contain opacity-100 skip-lazy\" data-parallax>\n\t\t\t\t\t<img decoding=\"async\" loading=\"eager\" src=\"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/themes\/cbd\/img\/content-logo-colorfull-2.svg\" alt=\"content-logo-colorfull\">\n\t\t\t\t<\/figure>\n\t\t\t\t\t\t<\/section>\n<!-- overview -->\t<section   class=\"s-overlay-img s-padding bg-red\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"row w-full lg:flex-row justify-between text-center lg:text-left gap-14 lg:gap-0 relative z-10\">\n\t\t\t\t\t\t\t\t<div class=\"w-full lg:py-10\">\n\t\t\t\t\t<div class=\"bg-white min-h-full py-12 px-10 lg:py-24 lg:pl-24 xl:pl-44 relative radius-20 z-10\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"content mt-8\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<p>EHC priznaje nedavne odluke nekoliko farmaceutskih tvrtki o obustavi ili preusmjeri razvoj ili komercijalizaciju terapija hemofilije od listopada 2024.<\/p>\n<p>Kao najnovija odluka me\u0111u njima, krajem velja\u010de 2025. Pfizer je najavio da \u0107e zaustaviti globalnu komercijalizaciju fidanakogena elaparvovec-dzkt, genske terapije za hemofiliju B, navode\u0107i nisku potra\u017enju. Odobrena u vi\u0161e regija, uklju\u010duju\u0107i Europsku uniju, ova jednokratna terapija vi\u0161e se ne\u0107e provoditi, a Pfizer je preusmjerio fokus na marstacimab-hncq, injekcijski tretman za hemofiliju A i B. <\/p>\n<p>EHC prepoznaje da ove odluke dolaze u vrijeme kada zna\u010dajne neispunjene potrebe i dalje postoje u zajednici osoba s poreme\u0107ajima zgru\u0161avanja. Iako je postignut napredak, mnoge osobe s hemofilijom (PWH) ili drugim poreme\u0107ajima zgru\u0161avanja i dalje se suo\u010davaju s problemima lije\u010denja, probojnim krvarenjem i smanjenom kvalitetom \u017eivota. Pristup standardnoj profilaksi i dalje predstavlja izazov u mnogim europskim zemljama, \u0161to dodatno nagla\u0161ava potrebu za kontinuiranim istra\u017eivanjima, inovacijama i dostupno\u0161\u0107u pravednog lije\u010denja.  <\/p>\n<p>EHC poziva farmaceutske tvrtke, zdravstvene vlasti i dionike da ostanu predani unapre\u0111enju mogu\u0107nosti lije\u010denja hemofilije i drugih poreme\u0107aja zgru\u0161avanja. Ulaganja u istra\u017eivanje i razvoj moraju se nastaviti kako bi se osiguralo da su potrebe zajednice oboljelih od poreme\u0107aja zgru\u0161avanja zadovoljene i da svi pacijenti imaju pristup sigurnim, u\u010dinkovitim i inovativnim terapijama. <\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"bottom mt-12\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.ehc.eu\/wp-content\/uploads\/2025\/02\/EHC-Statement-2025-02-26-.pdf\" target=\"_blank\" class=\"btn with-icon\">\n\t\t\t\t\t\t\t\t\t<span>Read the full EHC Statement here<\/span>\n\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Nakon odluke Pfizera da zaustavi globalnu komercijalizaciju fidanacogene elaparvovec-dzkt, EHC poziva farmaceutske tvrtke, zdravstvene vlasti i dionike da ostanu predani napretku lije\u010denja hemofilije i drugih poreme\u0107aja zgru\u0161avanja.<\/p>\n","protected":false},"author":4,"featured_media":3845,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[55],"tags":[167,155],"class_list":["post-6090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-hr","tag-azuriranje-lijecenja","tag-izjava-ehc-a"],"acf":[],"jetpack_featured_media_url":"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/uploads\/2025\/02\/treatment-update.jpg?strip=all&sharp=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts\/6090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/comments?post=6090"}],"version-history":[{"count":1,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts\/6090\/revisions"}],"predecessor-version":[{"id":6093,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts\/6090\/revisions\/6093"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/media\/3845"}],"wp:attachment":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/media?parent=6090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/categories?post=6090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/tags?post=6090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}